Visualizing Mechanisms of Bispecific Antibodies in Large B-Cell Lymphomas: Current Efficacy and Safety Data for Application in Relapsed/Refractory Populations
July 27, 2023
July 27, 2024
This activity is provided by Med Learning Group.
This activity is co-provided by AMEDCO
Nursing learners, view this Learner Notification prior to starting this activity
This activity is supported by a medical educational grant from Genmab and AbbVie Inc..
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 ANCC Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team.
In this innovative program integrating Virtual Reality animations, clinicians will visualize mechanisms of action for bispecific antibodies and recognize the rationale for application of these therapies in relapsed/refractory large B-cell lymphomas. By visualizing mechanisms, recognizing current clinical trial data informing the use of bispecific antibodies for large B-cell lymphomas, and understanding the potential for adverse events associated with bispecific antibodies and other therapies, clinicians will be better able to select appropriate therapy and monitor for potential adverse events in a highly multidisciplinary oncology practice setting.
After participating in this program, participants will be better able to:
- Analyze the mechanistic features of bispecific antibodies and rationale for use in relapsed/refractory large B-cell lymphomas
- Evaluate current clinical trial data informing use of bispecific antibodies in in relapsed/refractory large B-cell lymphomas
- Summarize best practices for management of potential adverse events with bispecific antibodies in large B-cell lymphomas in a multidisciplinary practice setting
Marco Ruella, MD
Assistant Professor of Medicine
Division of Hematology and Oncology
Perelman Center for Advanced Medicine
University of Pennsylvania
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™ Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationship(s)
- Marco Ruella, MD
- Royalty: Multiple patents on CART immunotherapy managed by the University of Pennsylvania and licensed to Novartis
- Receipt of Intellectual Property / Patent Holder: Tmunity (Kite), and ViTToria Biotherapeutics. Multiple patents on CART immunotherapy managed by the University of Pennsylvania and licensed to Novartis
- Consulting Fee: Tmunity (Kite), and ViTToria Biotherapeutics, GLG, Sana Biotechnology, Inc, Bristol Myers Squibb, GSK, NanoString, AbClon Inc.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Michael R. Page, PharmD, RPh, Medical Director for Med Learning Group, has nothing to disclose.
Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Amanda Jenkins, Program Manager for Med Learning Group has nothing to disclose.
Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Method of Participation
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete and submit the evaluation form to Med Learning Group
You will receive your certificate after the enduring activity.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: https://www.medlearninggroup.com/privacy-policy/
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Content - Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.